Updated: Reddy's Follows Endo On US Kuvan Launch
Sapropterin Market Worth Roughly $500m
Under the terms of a patent-litigation settlement from April 2017, Endo’s Par subsidiary has launched the first US generic versions of BioMarin’s Kuvan (sapropterin) tablet and powder formulations. Rival ANDA sponsor Dr Reddy’s has followed suit on the tablet formulation.
You may also be interested in...
Endo will focus on restructuring initiatives and new launches in 2021 to stabilize its generics business, after the company reported a 20% drop in generics sales for the fourth quarter of 2020, with full-year sales down by more than a tenth.
There is one orphan drug among the five new marketing authorization applications that the European Medicines Agency has under review. All five drugs will be reviewed under standard review timelines.
Endo’s Par has introduced the first generic version of Mallinckrodt’s chronic idiopathic constipation medicine Amitiza, realizing the terms of a settlement agreement announced more than six years ago.